Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Energy Cost of Walking and Its Association With Gait Parameters, Daily Activity, and Fatigue in Persons With Mild Multiple Sclerosis.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Mutations affecting segment number and polarity in Drosophila.
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Regression-Based Norms Improve the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS).
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Unraveling the secrets of white matter - Bridging the gap between cellular, animal and human imaging studies.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Reproductive issues in women with multiple sclerosis: ethical considerations.
Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene.
Association mapping of disease loci, by use of a pooled DNA genomic screen.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study.
Molecular targets of FTY720 (fingolimod).
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.
Pages
« first
‹ previous
…
114
115
116
117
118
119
120
121
122
…
next ›
last »